doi:10.3969/j.issn.1673-8640.2015.10.016

Abstract

CLC Number:

R446.1

Figures/Tables 5

References 11

[1]	VARKI A.Sialic acids in human health and disease[J]. Trends Mol Med,2008,14(8):351-360.
[2]	张嘉宁,汪淑晶. 唾液酸生物学与人类健康和疾病[J]. 生命科学,2011,23(7):678-684.
[3]	刘沛,王舒,李变荣. 血清唾液酸在恶性肿瘤诊断中的临床应用[J]. 检验医学与临床,2012,9(6):687-688.
[4]	National Committee for Clinical Laboratory Standards.Preliminary evaluation of quantitative clinical laboratory methods[S].EP10-A2,NCCLS,2002.
[5]	程明刚,程静,刘香萍,等.应用NCCLS EP10-A2文件初步评价定量钙测定的性能[J].热带医学杂志,2010,10(11):1289-1292.
[6]	刘怀平,刘树业.实验室认可中封闭检测系统的性能验证及评价[J].现代预防医学,2011,38(19):3981-3984.
[7]	张葵. 定量检测系统方法学性能验证实验的基本方法[J].临床检验杂志,2009,27(5):321-323.
[8]	National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices; approved guideline[S]. EP5-A2,NCCLS,1999.
[9]	National Committee for Clinical Laboratory Standards. Evaluation of the linearity of quantitative analytical methods: a statistical approach; approved guideline[S]. EP6-A,NCCLS,2003.
[10]	National Committee for Clinical Laboratory Standards. Method comparison and bias estimation using patient samples: approved guideline[S]. EP9-A2,NCCLS,2002.
[11]	National Committee for Clinical Laboratory Standards. Interference testing in clinical chemistry: approved guideline[S]. EP7-A2,NCCLS,2002.

时间	低值	中值	高值
第1天	55.1±0.6	107.8±0.3	160.5±1.2
第2天	54.8±0.3	108.1±0.5	160.8±1.0
第3天	55.0±0.5	107.7±1.0	160.9±0.6
第4天	55.5±0.3	107.7±0.2	160.8±0.9
第5天	55.1±0.4	107.2±0.3	160.5±0.6
总均值(Y)	55.1	107.7	160.7
靶值(X)	55.0	107.5	160.0
偏差(Y-X)	0.1	0.2	0.7
允许偏差	±2.8	±5.4	±8.0
可接受性评价	可接受	可接受	可接受

时间	低值	中值	高值
第1天	55.1±0.6	107.8±0.3	160.5±1.2
第2天	54.8±0.3	108.1±0.5	160.8±1.0
第3天	55.0±0.5	107.7±1.0	160.9±0.6
第4天	55.5±0.3	107.7±0.2	160.8±0.9
第5天	55.1±0.4	107.2±0.3	160.5±0.6
总均值(Y)	55.1	107.7	160.7
靶值(X)	55.0	107.5	160.0
偏差(Y-X)	0.1	0.2	0.7
允许偏差	±2.8	±5.4	±8.0
可接受性评价	可接受	可接受	可接受

项目	低值	中值	高值
合并批内方差(R)	0.17	0.30	0.73
日间均值方差(S)	0.07	0.10	0.03
校正的日间方(T)	0.01	0.00	0.00
总方差(U)	0.18	0.30	0.73
总标准偏差(V)	0.42	0.55	0.86
总均值(Y)	55.10	107.70	160.70
总不精密度[CV%(W)]	0.76	0.51	0.53
允许不精密度[CV(%)]	5	5	5
可接受性评价	可接受	可接受	可接受

项目	低值	中值	高值
合并批内方差(R)	0.17	0.30	0.73
日间均值方差(S)	0.07	0.10	0.03
校正的日间方(T)	0.01	0.00	0.00
总方差(U)	0.18	0.30	0.73
总标准偏差(V)	0.42	0.55	0.86
总均值(Y)	55.10	107.70	160.70
总不精密度[CV%(W)]	0.76	0.51	0.53
允许不精密度[CV(%)]	5	5	5
可接受性评价	可接受	可接受	可接受

批次	项目	截距	斜率	携带污染 (%)	非线性	漂移
1	数值	-0.085	1.004	0.546	0.000	0.058
	t值	-0.304	0.429	0.653	0.083	0.516
2	数值	-0.491	1.008	-0.312	0.000	0.096
	t值	-2.217	1.252	-0.469	-0.267	1.092
3	数值	-0.600	1.009	-0.388	0.000	-0.055
	t值	-2.136	1.083	-0.460	0.197	-0.494
4	数值	0.158	1.003	-0.412	0.000	-0.066
	t值	0.828	0.611	-0.717	0.640	-0.870
5	数值	-0.347	1.004	0.403	0.000	-0.059
	t值	-2.612	1.099	1.011	1.332	-1.106
总均值	数值	-0.273	1.006	-0.032	0.000	-0.005
	t值	-1.288	0.895	0.003	0.397	-0.172

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 11

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.